Use of Ceftazidime-Avibactam in Infants and Children

Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS


Pediatr Pharm. 2019;25(5) 

In This Article

Mechanism of Action

Avibactam is the first in a new class of synthetic beta-lactamase inhibitors that also has activity against carbapenemases.[2–4] It protects ceftazidime, a third generation cephalosporin with antipseudomonal activity, from being degraded by beta-lacatamases and extended-spectrum beta-lactamases (ESBLs), including TEM, SHV, CTX-M, Klebsiella pneumoniae carbapenemases (KPCs), AmpC, and some oxacillinases (OXA). The combination has also been shown to have in vitro activity against Pseudomonas aeruginosa in the presences of some AmpC beta-lactamases. It is generally ineffective against bacteria producing metallo-beta-lactamases, but has been successful in the treated New Delhi metallo-beta-lactamase (NDM-1) producing strains of K. pneumoniae and Morganella morganii when used in combination with aztreonam.